Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Moderate Buy consensus from 19 analysts (17 buy, 1 sell, 1 strong buy) with an average 12‑month target price of $291.56.
• Ascendis missed Q EPS (loss of $0.64 vs. -$0.06 expected) but slightly beat revenue ($290.4M vs. $285.4M), and sell‑side analysts forecast 4.13 EPS for the current year.
• The stock trades around $221.81 (52‑week range $150.89–$250.74) with a market cap of $13.8B and a negative P/E, and the company’s lead product is once‑weekly growth hormone Skytrofa built on its TransCon platform.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nineteen analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $291.5556.

A number of research firms have issued reports on ASND. Morgan Stanley reaffirmed an "overweight" rating and issued a $256.00 target price on shares of Ascendis Pharma A/S in a report on Thursday, February 12th. Bank of America increased their price objective on Ascendis Pharma A/S from $262.00 to $292.00 and gave the company a "buy" rating in a research report on Thursday, April 16th. Barclays began coverage on Ascendis Pharma A/S in a research report on Tuesday, January 27th. They issued an "overweight" rating and a $342.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $300.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Finally, Jefferies Financial Group began coverage on shares of Ascendis Pharma A/S in a research note on Monday, March 16th. They set a "buy" rating and a $290.00 target price for the company.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock opened at $221.81 on Wednesday. Ascendis Pharma A/S has a fifty-two week low of $150.89 and a fifty-two week high of $250.74. The firm has a fifty day moving average price of $231.44 and a two-hundred day moving average price of $218.18. The firm has a market cap of $13.84 billion, a price-to-earnings ratio of -50.41 and a beta of 0.49.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Thursday, February 12th. The biotechnology company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.58). The firm had revenue of $290.38 million during the quarter, compared to analyst estimates of $285.35 million. As a group, sell-side analysts expect that Ascendis Pharma A/S will post 4.13 earnings per share for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several large investors have recently bought and sold shares of the stock. Leonteq Securities AG raised its stake in Ascendis Pharma A/S by 405.9% during the 1st quarter. Leonteq Securities AG now owns 855 shares of the biotechnology company's stock valued at $196,000 after purchasing an additional 686 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in Ascendis Pharma A/S by 243.0% during the 1st quarter. Pictet Asset Management Holding SA now owns 251,833 shares of the biotechnology company's stock valued at $56,907,000 after purchasing an additional 178,415 shares during the last quarter. Braun Stacey Associates Inc. raised its stake in Ascendis Pharma A/S by 10.0% during the 1st quarter. Braun Stacey Associates Inc. now owns 130,992 shares of the biotechnology company's stock valued at $29,962,000 after purchasing an additional 11,897 shares during the last quarter. ARS Investment Partners LLC raised its stake in Ascendis Pharma A/S by 20.0% during the 1st quarter. ARS Investment Partners LLC now owns 209,456 shares of the biotechnology company's stock valued at $47,909,000 after purchasing an additional 34,845 shares during the last quarter. Finally, Corient Private Wealth LLC raised its stake in Ascendis Pharma A/S by 17.7% during the 4th quarter. Corient Private Wealth LLC now owns 3,393 shares of the biotechnology company's stock valued at $724,000 after purchasing an additional 510 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.